Michael Morabito
Stock Analyst at Chardan Capital
(n/a)
# 4,324
Out of 4,789 analysts
11
Total ratings
9.09%
Success rate
-28.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Morabito
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Maintains: Buy | $79 → $81 | $40.48 | +100.10% | 2 | Mar 17, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $202 → $203 | $331.23 | -38.71% | 2 | Feb 26, 2021 | |
| DRRX DURECT | Maintains: Buy | $70 → $80 | $0.80 | +9,875.06% | 2 | Feb 3, 2021 | |
| ETNB 89bio | Maintains: Buy | $59 → $95 | $7.27 | +1,206.74% | 3 | Sep 15, 2020 | |
| VKTX Viking Therapeutics | Maintains: Buy | $15 → $20 | $24.15 | -17.18% | 2 | Aug 31, 2020 |
Akero Therapeutics
Mar 17, 2021
Maintains: Buy
Price Target: $79 → $81
Current: $40.48
Upside: +100.10%
Madrigal Pharmaceuticals
Feb 26, 2021
Maintains: Buy
Price Target: $202 → $203
Current: $331.23
Upside: -38.71%
DURECT
Feb 3, 2021
Maintains: Buy
Price Target: $70 → $80
Current: $0.80
Upside: +9,875.06%
89bio
Sep 15, 2020
Maintains: Buy
Price Target: $59 → $95
Current: $7.27
Upside: +1,206.74%
Viking Therapeutics
Aug 31, 2020
Maintains: Buy
Price Target: $15 → $20
Current: $24.15
Upside: -17.18%